LinkedIn
Specialty
Course Type
Search
Log In
Specialty
Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In
Menu

From Trials to Treatments: Inflammatory Events Following Intravitreal Injection: Infectious Endophthalmitis vs Sterile Inflammatory Responses – Part 3

By: Rishi Singh, MD; Charles C. Wykoff, MD, PhD

Begin Course
Webinar Credits: 1

Expiration Date: Sunday, June 30, 2019
Release Date: June 13, 2018

Learning Objectives

Upon completion of this activity, the participant should be able to: 

  • Recognize the importance of early diagnosis and treatment of age-related macular degeneration and diabetic macular edema
  • Assess the response of anti-vascular endothelial growth factor intravitreal injections, and define “suboptimal responders”
  • Understand the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and RVO
  • Discuss the outcomes of pivotal studies in AMD, DME, and RVO and how study results may differ from “real-world” dosing methods
  • Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe
  • Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

Rishi P. Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alcon; Allergan  Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Charles Wykoff, MD, PhD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant:  Alimera Sciences, Inc.; Allergan, plc; Alnylam; Bayer Pharmaceuticals; Clearside Biomedical, Inc.; CORCEPT; DORC International; EyePoint/pSivida; Genentech, Inc.; Notal Vision; Novartia; ONL Therapeutics; Regeneron Pharmaceuticals, Inc; Roche; and Santen Pharmaceuticals. Speaker’s Bureau:  Allergan, plc. and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Adverum; Aerpio; Alcon; Aldeyra; Allegro Ophthalmics; Allergan, Inc.; Apellis Pharmaceuticals; Astellas; Aura; Boehringer Ingelheim; Chiltern; Clearside Biomedical, Inc.; EyePoint/pSivida; Genentech, Inc; Heidleberg; Iconic Therapeutics; John’s Hopkins University; NEI; Novartis; OHR; Opthotech Corporation; Regeneron Pharmaceuticals, Inc; Regenxbio; Roche; Santen Pharmaceutical Co., Ltd.; SciFlour; Taiwan Liposome Company; and Tyrogenex.

EDITORIAL SUPPORT DISCLOSURES

Erin K. Fletcher, MIT, director of compliance and education, Evolve, has no financial relationships with commercial interests.

Susan Gallagher-Pecha, director of client services and project management, Evolve, has no financial relationships with commercial interests.

Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve  or Regeneron Pharmaceuticals, Inc.

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Pretest

Video Resources

Next

Test

Instructions

To receive AMA PRA Category 1 Credit™, you must complete the Pretest/Posttest/Activity Evaluation/Satisfaction Measures. Please proceed.

Step 1 of 3

33%
  • AgreeNeutralDisagree
    Recognize the importance of early diagnosis and treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME).
    Assess the response of anti-vascular endothelial growth factor (VEGF) intravitreal injections and define “suboptimal responders.”
    Understand the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and retinal vein occlusion (RVO).
    Discuss the outcomes of pivotal studies in AMD, DME, and RVO and how study results may differ from real-world dosing methods.
    Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe.
    Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.
Back